Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) Receives $17.67 Average Target Price from Analysts

Shares of Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) (TSE:AUP) have been assigned a consensus recommendation of “Moderate Buy” from the six ratings firms that are covering the company, MarketBeat.com reports. Three analysts have rated the stock with a hold recommendation, two have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12 month target price among analysts that have updated their coverage on the stock in the last year is $17.6667.

AUPH has been the subject of a number of analyst reports. Zacks Research downgraded Aurinia Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Tuesday, July 21st. Wall Street Zen cut shares of Aurinia Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Saturday, August 8th. Weiss Ratings raised shares of Aurinia Pharmaceuticals from a “hold (c+)” rating to a “buy (b-)” rating in a report on Wednesday, August 26th. Bloom Burton upgraded shares of Aurinia Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research note on Thursday, August 20th. Finally, Royal Bank Of Canada increased their price target on shares of Aurinia Pharmaceuticals from $15.00 to $16.00 and gave the stock a “sector perform” rating in a report on Friday, August 7th.

Hedge Funds Weigh In On Aurinia Pharmaceuticals

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. BOK Financial Private Wealth Inc. purchased a new stake in shares of Aurinia Pharmaceuticals during the fourth quarter worth about $32,000. Nykredit A S acquired a new position in shares of Aurinia Pharmaceuticals during the 2nd quarter worth about $35,000. Global Retirement Partners LLC purchased a new position in Aurinia Pharmaceuticals in the 2nd quarter valued at about $41,000. Quantbot Technologies LP purchased a new position in Aurinia Pharmaceuticals in the 2nd quarter valued at about $45,000. Finally, Northwestern Mutual Wealth Management Co. acquired a new stake in Aurinia Pharmaceuticals in the 3rd quarter worth about $48,000. 36.83% of the stock is owned by hedge funds and other institutional investors.

Aurinia Pharmaceuticals Price Performance

Shares of AUPH opened at $16.08 on Thursday. The business’s 50-day moving average is $15.81 and its two-hundred day moving average is $15.55. The company has a market capitalization of $2.14 billion, a P/E ratio of 7.02 and a beta of 1.40. Aurinia Pharmaceuticals has a fifty-two week low of $10.34 and a fifty-two week high of $19.25. The company has a debt-to-equity ratio of 0.07, a quick ratio of 4.97 and a current ratio of 5.42.

Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) last issued its quarterly earnings data on Thursday, August 6th. The biotechnology company reported $0.28 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.24 by $0.04. Aurinia Pharmaceuticals had a return on equity of 26.11% and a net margin of 100.84%.The business had revenue of $58.57 million during the quarter, compared to analysts’ expectations of $80.45 million. Research analysts predict that Aurinia Pharmaceuticals will post 0.79 earnings per share for the current year.

Aurinia Pharmaceuticals Company Profile

Aurinia Pharmaceuticals Inc is a clinical?stage biopharmaceutical company focused on developing and commercializing therapies for autoimmune diseases. The company’s proprietary molecule, voclosporin, is designed to selectively inhibit calcineurin and reduce inflammation associated with autoimmune responses. Aurinia operates research and development facilities in Canada and the United States, leveraging collaborations with academic institutions and contract research organizations to advance its clinical pipeline.

The company’s lead product, voclosporin (marketed as LUPKYNIS), received approval from the U.S.